myelosuppression


Also found in: Dictionary, Thesaurus, Legal, Encyclopedia, Wikipedia.

suppression

 [sŭ-presh´un]
the act of holding back or checking.
1. the stopping or inhibition of something, such as a secretion, excretion, normal discharge, or other function.
2. in psychiatry, conscious inhibition of an unacceptable impulse or idea as contrasted with repression, which is unconscious.
3. in genetics, a second mutation occurring at a site different from the first mutation site and able to mask or suppress the phenotypic expression of the first mutation; the organism appears to be reverted but is in fact doubly mutant.
4. inhibition of the erythrocytic stage of Plasmodium to prevent clinical attacks of malaria; used for prophylaxis.
5. cortical inhibition of perception of objects in all or part of the visual field of one eye during binocular vision.
bone marrow suppression reduction of the cell-forming functions of bone marrow, such as by a drug or because of replacement of the marrow by a disease process. Called also myelophthisis and myelosuppression.
labor suppression in the nursing interventions classification, a nursing intervention defined as controlling uterine contractions prior to 37 weeks of gestation to prevent preterm birth. See also labor.
lactation suppression in the nursing interventions classification, a nursing intervention defined as facilitating the cessation of lactation and minimizing breast engorgement after childbirth.
overdrive suppression the suppression of intrinsic cellular automaticity by a rapid outside stimulus. In cardiology this refers to the inhibitory effect of a faster pacemaker on a slower pacemaker. The faster rate causes an accumulation of intracellular sodium, stimulating the sodium-potassium pump, which hyperpolarizes the cell so that it takes longer to reach threshold potential. This phenomenon is present in healthy His-Purkinje cells but decreases with a decrease in membrane potential and loss of fast sodium channels.

myelosuppression

/my·elo·sup·pres·sion/ (-sŭ-presh´un) bone marrow suppression.

myelosuppression

[-səpresh′ən] .

myelosuppression

Oncology The suppression–usually an undesired side effect–of normal BM activity, often the result of RT, chemotherapy, or various toxins. Cf Myelosuppressive therapy.

my·e·lo·sup·pres·sion

(mī'ĕ-lō-sŭ-presh'ŭn)
A reduction in the ability of the bone marrow to produce blood cells: platelets, red blood cells, and white blood cells. Typically caused by cancer chemotherapy and radiation therapy. During the period of myelosuppression, patients may be at an increased risk of infection or bleeding or may experience symptoms of anemia.
[G. myelos, marrow, + L. suppressio, pressing under]

my·e·lo·sup·pres·sion

(mī'ĕ-lō-sŭ-presh'ŭn)
A reduction in the ability of the bone marrow to produce blood cells: platelets, red blood cells, and white blood cells.
[G. myelos, marrow, + L. suppressio, pressing under]

myelosuppression

(mī´əlōsəpres´hən),
n the suppression of blood cell and platelet production in the bone marrow.

myelosuppression

depression of bone marrow activity.
References in periodicals archive ?
A review of the Chemotherapy Induced Myelosuppression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy.
The numbers of patients who developed a rash (n = 3) or pancreatitis (n = 2) were small, and myelosuppression was not observed during the course of the study and could not be analyzed.
Myelosuppression as seen from the WBC count was observed through out the period of CTX administration.
Medical treatments (CSF, EPO or IL-11) were provided to the patients with myelosuppression.
Biopharmaceutical company Cleveland BioLabs (NASDAQ:CBLI) disclosed on Thursday the allowance of a US patent application that covers composition of matter for CBLB612, an investigational drug in development for mobilisation of hematopoietic stem cells (HSCs) and for the prevention of chemotherapy-induced myelosuppression.
The rates of myelosuppression with the same and similar regimens vary greatly, making it difficult to determine the actual risk for neutropenic complications associated with common therapeutic regimens like R-CHOP9.
Side effects include myelosuppression, edema, gastrointestinal symptoms, headache, and rash.
There are three important mutations in the TPMT gene, and individuals with low TPMT activity build up high drug levels leading to myelosuppression that is sometimes severe.
Apart from the variability of myelosuppression, the compound demonstrated a superior safety profile in comparison to other cytotoxics.